Laminin receptor 1 precursor protein (37LRP) epitope delineated by an hepatocellular carcinoma specific antibody

Abstract

This invention relates to the diagnosis and treatment of cancerous diseases, particularly to such diagnosis and treatment which revolves around the ability of the 5LAC-23 monoclonal antibody (or antigenic binding fragments derived therefrom) to bind with the Laminin Receptor 1 Precursor Protein 37LRP; and most particularly to diagnosis and treatment of Hepatocellular Carcinoma by various means which rely upon direct binding of 5LAC-23 with the particular antigenic moiety specifically recognized thereby and generally overexpressed in Hepatocellular carcinoma cells. The invention additionally relates to the treatment of such cells with conjugated moieties effective to aid in differentiation, treatment and diagnostic imaging thereof.

1 . A process for differentiation, treatment, or diagnostic imaging of cells which express 37LRP comprising:
 providing a sample of said cells;   providing a conjugated moiety including an isolated monoclonal antibody or antigen binding fragment thereof, said isolated monoclonal antibody or antigen binding fragment thereof being an isolated monoclonal antibody or antigen binding fragment thereof which binds to an expressed 37LRP antigenic moiety, said antigenic moiety characterized as being bound by the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as PTA-5690, said isolated monoclonal antibody or antigenic binding fragment thereof being conjugated with at least one member selected from the group consisting of drugs, toxins, enzymes, or radioactive compounds;   whereby binding of said conjugated moiety with said cells results in differentiation, treatment, or diagnostic imaging of said cells.   
     
     
         2 . A method for treating a patient suffering from a cancerous disease comprising:
 providing a conjugated moiety including an isolated monoclonal antibody or antigen binding fragment thereof, said isolated monoclonal antibody or antigen binding fragment thereof being an isolated monoclonal antibody or antigen binding fragment thereof which binds to an expressed 37LRP antigenic moiety, said antigenic moiety characterized as being bound by the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as PTA-5690, said isolated monoclonal antibody or antigenic binding fragment thereof being conjugated with at least one member selected from the group consisting of drugs, toxins, enzymes, or radioactive compounds; and   administering said conjugated moiety to said patient.   
     
     
         3 . The method of  claim 1  wherein said isolated monoclonal antibody is a humanized version of the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as PTA-5690 or antigenic binding fragment thereof. 
     
     
         4 . The method of  claim 1  wherein said isolated monoclonal antibody is a chimeric version of the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as PTA-5690 or antigenic binding fragment thereof. 
     
     
         5 . The method of  claim 2  wherein said isolated monoclonal antibody is a humanized version of the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as PTA-5690 or antigenic binding fragment thereof. 
     
     
         6 . The method of  claim 1  wherein said isolated monoclonal antibody is a chimeric version of the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as PTA-5690 or antigenic binding fragment thereof.